Clinical Trial: A Two Year Investigational Drug Study to Assess Weight Loss in Obese Patients

This study is not yet open for patient recruitment.
Verified by Merck August 2005

Sponsored by: Merck
Information provided by: Merck Identifier: NCT00131391


A two year worldwide study in obese patients to assess the safety and tolerability as well as the effects of treatment with an investigational drug for weight loss on body weight and metabolic syndrome.
Condition Intervention Phase
 Drug: An Investigational Drug for Weight Loss
Phase II

MedlinePlus related topics:  Obesity

Study Type: Interventional
Study Design: Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study


Ages Eligible for Study:  18 Years and above,  Genders Eligible for Study:  Both

Inclusion Criteria:

  • Body Mass Index (BMI) between 30-43 kg/m2

Exclusion Criteria:

  • History of major psychiatric disorder
  • Blood pressure greater than 160/100
  • Fasting blood glucose greater than 126 mg/dL
  • Triglycerides greater than 600 mg/dL

Location and Contact Information

Please refer to this study by identifier  NCT00131391

Toll Free Number      1-888-577-8839 

Study chairs or principal investigators

Medical Monitor,  Study Director,  Merck   

More Information

Study ID Numbers:  2005_034
Last Updated:  August 17, 2005
Record first received:  August 16, 2005 Identifier:  NCT00131391
Health Authority: United States: Food and Drug Administration processed this record on 2005-08-23

Common Treatments

[ Disclaimer: The information on GoldBamboo for any particular treatment, medicine, drug, or herbal product might be missing or incomplete, and should never be used as a single source of knowledge. GoldBamboo generally has links to authoritative sites displayed toward the bottom of each topic page under the heading "Resources". ]

Follow Us